Back to top
more

89BIO (ETNB)

(Real Time Quote from BATS)

$9.29 USD

9.29
647,666

+0.15 (1.64%)

Updated Nov 4, 2024 02:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy

by Zacks Equity Research

89BIO (ETNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success

by Zacks Equity Research

Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

by Zacks Equity Research

Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.

Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

89BIO (ETNB) Just Overtook the 200-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for 89BIO (ETNB) points to a 168.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Akero (AKRO) Slumps 63% on Mixed Results From NASH Study

by Zacks Equity Research

Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.

ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study

by Zacks Equity Research

ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.

Are Medical Stocks Lagging 89BIO (ETNB) This Year?

by Zacks Equity Research

Here is how 89BIO (ETNB) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.

Ultragenyx (RARE) Doses First Patients in Bone Disease Studies

by Zacks Equity Research

Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.

89BIO (ETNB) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for 89BIO (ETNB) points to a 57.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Allogene Therapeutics (ALLO) and 89BIO (ETNB) have performed compared to their sector so far this year.

Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for 89BIO (ETNB) points to a 79.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how 89BIO (ETNB) and Henry Schein (HSIC) have performed compared to their sector so far this year.

89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study

by Zacks Equity Research

Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.

Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for 89BIO (ETNB) points to an 80% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.

Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug

by Zacks Equity Research

Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product

Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.

Zacks.com featured highlights Coty, OneSpaWorld, Mueller Water Products and 89BIO

by Zacks Equity Research

Coty, OneSpaWorld, Mueller Water Products and 89BIO have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy for Superb Returns

by Tirthankar Chakraborty

Coty (COTY), OneSpaWorld (OSW), Mueller Water Products (MWA) and 89BIO (ETNB) have been selected as the breakout stocks for today.

Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.